Hinova Pharmaceuticals Inc. A Working Capital to Net Assets Ratio
Hinova Pharmaceuticals Inc. A working capital to net assets ratio. Hinova Pharmaceuticals Inc. A (688302) has a Working Capital to Net Assets ratio of 77.3% as of June 2025. Working capital of CN¥879.45 Million (current assets of CN¥1.01 Billion minus current liabilities of CN¥134.32 Million) is measured against net assets of CN¥1.14 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of Hinova Pharmaceuticals Inc. A to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Hinova Pharmaceuticals Inc. A (2019–2024)
Working capital to net assets ratio of Hinova Pharmaceuticals Inc. A from 2019 to 2024. This chart shows how Hinova Pharmaceuticals Inc. A's Working Capital to Net Assets ratio has evolved across 6 annual periods from 2019 to 2024. As of June 2025, the ratio stands at 77.3%, reflecting working capital of CN¥879.45 Million against net assets of CN¥1.14 Billion CNY. See 688302 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Hinova Pharmaceuticals Inc. A Working Capital to Net Assets Ratio by Year (2019–2024)
Hinova Pharmaceuticals Inc. A working capital to net assets ratio by year from 2019 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Hinova Pharmaceuticals Inc. A from 2019 to 2024, covering 6 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see total assets of Hinova Pharmaceuticals Inc. A.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 61.9% | CN¥738.59 Million | CN¥1.19 Billion | CN¥885.54 Million | CN¥146.95 Million | ▼ -14.2 pp |
| 2023 | 76.1% | CN¥1.04 Billion | CN¥1.37 Billion | CN¥1.15 Billion | CN¥106.84 Million | ▼ -16.8 pp |
| 2022 | 92.9% | CN¥1.47 Billion | CN¥1.59 Billion | CN¥1.61 Billion | CN¥138.27 Million | ▼ -3.9 pp |
| 2021 | 96.8% | CN¥763.91 Million | CN¥788.76 Million | CN¥955.24 Million | CN¥191.33 Million | ▼ -2.8 pp |
| 2020 | 99.7% | CN¥982.80 Million | CN¥986.15 Million | CN¥1.18 Billion | CN¥199.52 Million | ▼ -13.8 pp |
| 2019 | 113.4% | CN¥-40.60 Million | CN¥-35.78 Million | CN¥39.90 Million | CN¥80.50 Million | — |